<DOC>
	<DOC>NCT02946008</DOC>
	<brief_summary>This is a single-arm prospective non-randomized, non-blinded trial to assess the safety of neoadjuvant stereotactic body radiation therapy (SBRT) before surgery in high risk prostate cancer patients. Radiation therapy will be delivered over 5 treatment sessions for approximately 1.5 weeks total.</brief_summary>
	<brief_title>A Phase I Trial of Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for High Risk Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Subjects must have biopsyconfirmed adenocarcinoma of the prostate. Subjects must have a negative bone scan. Subjects must have one of the following risk factors: PSA ≥20 and/or Gleason score ≥8 and/or Clinical or radiographic stage ≥T3a per AJCC (American Joint Committee on Cancer) 7th Edition Staging Manual and/or Radiographic pelvic lymph node positive disease and/or At least two out of four of the following: PSA (Prostate Specific Antigen) 1019.9, GS (Gleason Score) = 3+4, clinical stage = T2b/T2c, ≥50% positive biopsy cores. Subjects must freely sign informed consent to enroll in the study. Subjects must be medically fit to undergo surgery determined by the PI. Age ≥ 18 KPS Karnofsky Performance Status (performance status is an attempt to quantify cancer patients' general wellbeing and activities of daily life, scores range from 0 to 100 where 100 represents perfect health and 0 represents death): ≥70. No prior invasive malignancy in the past 3years, except nonmelanomatous skin cancer unless disease free for a minimum of 2 years. Carcinoma insitu of the bladder or head and neck region is permissible. Subjects must not have had prior pelvic radiation therapy, Subjects must not have had prior androgen deprivation therapy in the past 6 months. Metastatic disease as demonstrated by bone scan, CT scan or MRI (Magnetic Resonance Imaging) of the pelvis, or chest xray. Declared highrisk for anesthesia by attending anesthesiologist, cardiologist, or other physician. History of prior pelvic radiation therapy. History of androgen deprivation therapy within the past 6 months.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>